Adlai Nortye Ltd ADR (ANL)

Currency in USD
1.55
+0.05(+3.33%)
Closed·
After Hours
1.550.00(0.00%)
·
ANL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
ANL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.501.55
52 wk Range
1.103.89
Key Statistics
Prev. Close
1.5
Open
1.5
Day's Range
1.5-1.55
52 wk Range
1.1-3.89
Volume
2.79K
Average Volume (3m)
9.09K
1-Year Change
-51.3%
Book Value / Share
0.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.00
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Adlai Nortye Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Adlai Nortye Ltd ADR Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Compare ANL to Peers and Sector

Metrics to compare
ANL
Peers
Sector
Relationship
P/E Ratio
−1.1x−1.9x−0.5x
PEG Ratio
−0.01−0.010.00
Price/Book
2.2x1.9x2.6x
Price / LTM Sales
-10.0x3.3x
Upside (Analyst Target)
-195.4%42.8%
Fair Value Upside
Unlock11.2%6.5%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ANL Income Statement

People Also Watch

174.46
ALAB
+28.71%
42.68
AAPG
+1.62%
5.6000
UPXI
+6.26%
4.065
PRME
-6.98%
1.890
IPA
+4.42%

FAQ

What Stock Exchange Does Adlai Nortye ADR Trade On?

Adlai Nortye ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Adlai Nortye ADR?

The stock symbol for Adlai Nortye ADR is "ANL."

What Is the Adlai Nortye ADR Market Cap?

As of today, Adlai Nortye ADR market cap is 55.35M.

What Is Adlai Nortye ADR's Earnings Per Share (TTM)?

The Adlai Nortye ADR EPS (TTM) is -1.62.

When Is the Next Adlai Nortye ADR Earnings Date?

Adlai Nortye ADR will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is ANL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Adlai Nortye ADR Stock Split?

Adlai Nortye ADR has split 0 times.

How Many Employees Does Adlai Nortye ADR Have?

Adlai Nortye ADR has 123 employees.

What is the current trading status of Adlai Nortye ADR (ANL)?

As of 07 Aug 2025, Adlai Nortye ADR (ANL) is trading at a price of 1.55, with a previous close of 1.50. The stock has fluctuated within a day range of 1.50 to 1.55, while its 52-week range spans from 1.10 to 3.89.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.